论文部分内容阅读
目的分析雷珠单抗在治疗糖尿病黄斑水肿(DME)与视网膜静脉阻塞性黄斑水肿(RVO-ME)的效果。方法随机选取2014年2月至2015年10月于内蒙古医科大学附属医院治疗的DME和RVO-ME患者共200例,共330只患眼。其中DME组有170只患眼,ROV-ME组有160只患眼。患者注射雷珠单抗,用量为0.5 mg/0.5 ml,注射前1 d,后1 d、2周、4周分别进行回访,观察患者最佳矫正视力(BCVA)和中央黄斑厚度(CST)。结果注射雷珠抗体1 d、2周、4周后,两组患者的BCVA逐渐改善,差异有统计学意义(P<0.05);注射4周后,两组患者的CST明显降低,差异有统计学意义(P<0.05);两组在治疗效果方面差异无统计学意义。两组患者在注射雷珠单抗后及后期回访中均未出现与雷珠单抗和玻璃体腔注射有关的并发症。结论雷珠单抗治疗DME与RVO-ME患者可以有效消除水肿,提升视力,安全性好。
Objective To analyze the effect of ranibizumab in the treatment of diabetic macular edema (DME) and retinal vein occlusive macular edema (RVO-ME). Methods A total of 200 DME and RVO-ME patients were randomly selected in the Affiliated Hospital of Inner Mongolia Medical University from February 2014 to October 2015. A total of 330 eyes were involved. There were 170 eyes in DME group and 160 eyes in ROV-ME group. Patients were given ranibizumab at doses of 0.5 mg / 0.5 ml, 1 d before, 1 d, 2 wk, and 4 wk respectively. The best corrected visual acuity (BCVA) and central macular thickness (CST) were observed. Results The BCVA of both groups gradually improved after 1, 2 weeks and 4 weeks of injection of bead antibody (P <0.05). After 4 weeks of injection, the CST of both groups decreased significantly (P <0.05). There was no significant difference in the therapeutic effect between the two groups. No complications associated with ranibizumab and intravitreal injection were observed in both groups after and after ranibizumab. Conclusions Ralizumab treatment of DME and RVO-ME patients can effectively eliminate edema, improve visual acuity, and good safety.